The North America organoid services market is projected to grow significantly, reaching approximately US$ 6.57 billion by 2031, up from US$ 1.64 billion in 2024, reflecting a robust compound annual growth rate (CAGR) of 21.9% during this period.
The organoid services market is experiencing rapid expansion due to the increasing demand for innovative screening services. By utilizing organoids derived from patients' cells, researchers can customize drug testing to individual responses, enhancing the chances of successful treatments through personalized approaches. The integration of advanced technologies, such as high-throughput screening and automated image analysis, further boosts the effectiveness of organoid screening services. This combination allows researchers to efficiently test numerous drug compounds, analyze results with greater accuracy, and expedite the drug discovery process. The global emphasis on innovative screening services, driven by the rise of personalized medicine and the need for faster drug development, supports the growth of the North America organoid services market.
In January 2024, HUB Organoids launched the IntegriGut Screen, a novel screening service that utilizes patient-derived organoid monolayers from inflammatory bowel disease (IBD) patients. This service provides high-quality human data on epithelial barrier function, facilitating the development of new therapies for IBD.
The increasing research and development activities, along with a growing demand for tissue engineering and organ transplantation, are propelling the organoid services market in the US. Organoids have the potential to address several limitations previously faced in biomedical research, such as gaining insights into human development, creating accurate disease models, and generating patient-matched tissues for regenerative medicine. Research funding and venture capital investments have also played a crucial role in advancing human organoid development. For example, a collaborative project funded by the National Science Foundation, valued at approximately US$ 1.5 million, aims to enhance brain organoid development processes and improve the consistency and reliability of end products for researchers.
Reasons to Buy
Executive Summary and Market Analysis
The market is divided into three primary regions: the United States, Canada, and Mexico, with the US anticipated to dominate the market share in 2024. Key drivers of growth in the organoid services market include the rising prevalence of chronic diseases and viral infections, the commercialization of organoid models, increased research and development activities, and advancements in stem cell research.Market Segmentation Analysis
The North America organoid services market can be segmented based on type, application, and source:
- By Type: The market includes various organoid types such as intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment is expected to hold the largest market share in 2024.
- By Application: Applications are categorized into developmental biology disease, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, among others. The developmental biology disease segment is projected to lead the market in 2024.
- By Source: The market is divided into pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells expected to dominate in 2024.
Market Outlook
Organoids are becoming essential tools for researchers and pharmaceutical developers, offering more efficient and precise methods for identifying promising drug candidates and predicting their effectiveness. The ability to create patient-derived organoids presents exciting opportunities for personalized drug screening. Unlike traditional 2D cell cultures, organoids replicate the complexity of human organs, including their cellular makeup, structure, and function, which leads to more accurate drug response predictions. This capability allows researchers to identify potential drug candidates with greater confidence, reducing the risk of costly failures in clinical trials.The organoid services market is experiencing rapid expansion due to the increasing demand for innovative screening services. By utilizing organoids derived from patients' cells, researchers can customize drug testing to individual responses, enhancing the chances of successful treatments through personalized approaches. The integration of advanced technologies, such as high-throughput screening and automated image analysis, further boosts the effectiveness of organoid screening services. This combination allows researchers to efficiently test numerous drug compounds, analyze results with greater accuracy, and expedite the drug discovery process. The global emphasis on innovative screening services, driven by the rise of personalized medicine and the need for faster drug development, supports the growth of the North America organoid services market.
In January 2024, HUB Organoids launched the IntegriGut Screen, a novel screening service that utilizes patient-derived organoid monolayers from inflammatory bowel disease (IBD) patients. This service provides high-quality human data on epithelial barrier function, facilitating the development of new therapies for IBD.
Country Insights
The North America organoid services market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2024. Companies in the US organoid services market are focusing on organic growth strategies to enhance their market presence. For instance, in February 2023, Molecular Devices, LLC and HUB Organoids announced a strategic partnership aimed at advancing next-generation 3D biology technologies to significantly reduce drug attrition rates from preclinical to clinical stages.The increasing research and development activities, along with a growing demand for tissue engineering and organ transplantation, are propelling the organoid services market in the US. Organoids have the potential to address several limitations previously faced in biomedical research, such as gaining insights into human development, creating accurate disease models, and generating patient-matched tissues for regenerative medicine. Research funding and venture capital investments have also played a crucial role in advancing human organoid development. For example, a collaborative project funded by the National Science Foundation, valued at approximately US$ 1.5 million, aims to enhance brain organoid development processes and improve the consistency and reliability of end products for researchers.
Company Profiles
Key players in the North America organoid services market include CUSABIO TECHNOLOGY LLC, Cyprio, Eurofins Scientific SE, HUB Organoids B.V., InnoSer, InSphero, LABTOO, Molecular Devices, LLC, Oncodesign Services, and Sino Biological Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America organoids services market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America organoids services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America organoids services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Organoids Services Market Landscape
5. North America Organoids Services Market - Key Market Dynamics
6. North America Organoids Services Market - Analysis
7. North America Organoids Services Market Analysis - by Type
8. North America Organoids Services Market Analysis - by Application
9. North America Organoids Services Market Analysis - by Source
10. North America Organoids Services Market - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the North America Organoids Services Market include:
- CUSABIO TECHNOLOGY LLC
- Cyprio
- Eurofins Scientific SE
- HUB Organoids B.V. (Hubrecht Organoid Technology)
- InnoSer
- InSphero
- LABTOO
- Molecular Devices, LLC.
- Oncodesign Services
- Sino Biological Inc.
